Cyclooxygenase-2 Inhibition and Cardiovascular Events
- 9 July 2002
- journal article
- editorial
- Published by Wolters Kluwer Health in Circulation
- Vol. 106 (2) , 167-169
- https://doi.org/10.1161/01.cir.0000025261.58465.62
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial InfarctionArchives of internal medicine (1960), 2002
- Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis.Archives of internal medicine (1960), 2002
- Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort studyThe Lancet, 2002
- Risk of Cardiovascular Events Associated With Selective COX-2 InhibitorsJAMA, 2001
- NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotectionThe Lancet, 2001
- Cyclooxygenase-2???Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis PatientsClinical Journal of Sport Medicine, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbitsProceedings of the National Academy of Sciences, 2000
- Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four casesArthritis & Rheumatism, 2000